BridgeBio has significantly improved the course of the innovative solution for cardiac amyloidosis, leveraging the compound. Early patient data suggests promising improvements for individuals affected with this severe https://attruby979674.aioblogs.com/94860326/company-progresses-amyloidosis-treatment-using-attruby